Secretary Kennedy's February 2026 peptide remarks, and what FDA did next
In February 2026, HHS Secretary Robert F. Kennedy Jr. made remarks on a podcast about peptide access. A remark and a formal FDA action are different things. Here's where the process actually stands.
TL;DR
- On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. said on The Joe Rogan Experience podcast that FDA would act on peptides soon and that about 14 peptides would become more accessible. It was an interview remark, not a formal HHS proposal, and no source shows he named specific peptides.
- The formal step was FDA's. On April 22, 2026, FDA removed 12 peptides from Category 2 after their nominations were withdrawn, including BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, and Semax. As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list.
- The Pharmacy Compounding Advisory Committee (PCAC) met on July 23–24, 2026 to review seven peptides. It voted to recommend adding BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon to the Section 503A bulk drug substances list, and voted against DSIP. The committee is advisory. As of September 2026, FDA has not made a final decision.
What it is
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. said on The Joe Rogan Experience podcast that FDA would act on peptides soon and that about 14 peptides would become more accessible. He said FDA had wrongly moved 19 peptides into Category 2 in September 2023. It was an interview remark, not a formal HHS proposal, directive, rule, or press release. No source shows he named specific peptides, and HHS did not publish a list or a Federal Register notice about it. The seven peptides FDA's advisory committee reviewed in July 2026 were BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, and Semax. All seven were among the 19 peptides FDA added to Category 2 on September 29, 2023.
How it works
Two different FDA processes are involved. The first is FDA's interim category list, which FDA changes by posting an updated list. On April 15, 2026, FDA gave notice that 12 peptides would leave Category 2 after seven days because their nominations were withdrawn. FDA removed them on April 22, 2026. Law firms say removal from Category 2 does not, by itself, put a substance on the bulks list or in Category 1. The second process is the Section 503A bulk drug substances list. The FDA's Pharmacy Compounding Advisory Committee reviews nominated substances and gives FDA a recommendation. On April 16, 2026, FDA published a Federal Register notice that scheduled the committee's July 2026 meeting. The committee's votes are advisory, and FDA makes the final decision.
Who asks about it
People come to this topic when they've seen news coverage of Secretary Kennedy's February 2026 podcast remarks and heard references to "peptides coming back" in podcasts or online discussions. The disconnect between "remark" and "available now" is causing real confusion. Patients and physicians are asking whether BPC-157 or TB-500 can now be prescribed through a licensed 503A pharmacy. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.
What the research says
HHS did not publish a document with the February 2026 remarks, so there is no formal HHS scientific rationale to cite. For some of the seven peptides — particularly BPC-157, which has an extensive animal literature on tissue repair — FDA's 2023 decision had been criticized by some researchers as premature given the volume of published preclinical data. In the February 2026 interview, Secretary Kennedy said FDA had wrongly moved 19 peptides into Category 2 in September 2023. FDA's Pharmacy Compounding Advisory Committee met on July 23–24, 2026 to review seven peptides for the Section 503A bulk drug substances list. For BPC-157 and for TB-500, the committee voted 8 yes, 6 no, and 1 abstention to recommend adding each to the Section 503A bulk drug substances list. It also voted to recommend KPV, MOTS-c, Semax, and Epitalon, and voted against emideltide (DSIP). The committee is advisory; as of September 2026, FDA has not made a final decision.
What to know before considering it
Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Sourcing these compounds outside of licensed pharmacy channels does not carry the legal or quality-control protections of 503A compounding. Halftime Health will update its formulary through licensed clinical channels if FDA's decisions change the status of the other five.
The Halftime POV
The February 2026 remarks mattered as a signal, and FDA's April 2026 list change followed. But the distance between a policy signal and a clinical reality is real, and the responsible position is to describe that distance accurately. We followed the July 2026 PCAC meeting, and we'll follow FDA's final decisions closely and update our content when the regulatory status formally changes.
Related reading:
FAQ
Q: What did Secretary Kennedy say about peptides in February 2026? A: It was not a formal HHS announcement. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. said on The Joe Rogan Experience podcast that FDA would act on peptides soon and that about 14 peptides would become more accessible. He said FDA had wrongly moved 19 peptides into Category 2 in September 2023. No source shows he named specific peptides, and HHS did not publish a list or a Federal Register notice about it. The formal step was FDA's April 2026 change to its category list.
Q: Did Secretary Kennedy's February 2026 remarks change peptide access? A: The remarks alone did not change anything. The formal step was FDA's: on April 22, 2026, FDA removed 12 peptides, including BPC-157 and TB-500, from Category 2 after their nominations were withdrawn. As of September 14, 2026, those peptides are not in any FDA 503A category and are not on the 503A bulks list. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
Q: When might Category 2 peptides become available? A: FDA removed 12 peptides from Category 2 on April 22, 2026. That did not put them on the 503A bulks list or in Category 1. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the Section 503A bulk drug substances list, and voted against emideltide (DSIP). The committee is advisory. As of September 14, 2026, FDA has not made a final decision. Halftime Health will update this post when the status changes.
Disclaimer
Several peptides discussed in this article — including KPV, MOTS-c, DSIP, epitalon, and Semax — were previously in FDA's Category 2. FDA removed them from Category 2 on April 22, 2026. As of September 14, 2026, they are not in any FDA 503A category and are not on the 503A bulks list. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Robert F. Kennedy Jr., HHS Secretary. Remarks on peptides, The Joe Rogan Experience podcast, February 27, 2026. HHS issued no press release or Federal Register notice.
- FDA. PCAC 2023 Meeting Summary. FDA.gov
- FDA. "Bulk Drug Substances That May Be Used in Compounding Under Section 503A." FDA.gov
- Federal Register. PCAC Nominations and Proposed Rules (search "503A bulk drug substances"). FederalRegister.gov
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What did Secretary Kennedy say about peptides in February 2026?
It was not a formal HHS announcement. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. said on The Joe Rogan Experience podcast that FDA would act on peptides soon and that about 14 peptides would become more accessible. He said FDA had wrongly moved 19 peptides into Category 2 in September 2023. No source shows he named specific peptides, and HHS did not publish a list or a Federal Register notice about it. The formal step was FDA's April 2026 change to its category list.
Did Secretary Kennedy's February 2026 remarks change peptide access?
The remarks alone did not change anything. The formal step was FDA's: on April 22, 2026, FDA removed 12 peptides, including BPC-157 and TB-500, from Category 2 after their nominations were withdrawn. As of September 14, 2026, those peptides are not in any FDA 503A category and are not on the 503A bulks list. As of September 2026, FDA has not made a final decision on BPC-157 or TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted separately on each. Both votes were 8 yes, 6 no, and 1 abstention to recommend adding the peptide to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Halftime Health protocols are prescribed by licensed physicians and prepared by licensed 503A compounding pharmacies. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.
When might Category 2 peptides become available?
FDA removed 12 peptides from Category 2 on April 22, 2026. That did not put them on the 503A bulks list or in Category 1. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the Section 503A bulk drug substances list, and voted against emideltide (DSIP). The committee is advisory. As of September 14, 2026, FDA has not made a final decision. Halftime Health will update this post when the status changes.
Keep reading
Every protocol is reviewed by a licensed physician and filled by a licensed 503A compounding pharmacy.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.